Skip to main content
. Author manuscript; available in PMC: 2008 Feb 5.
Published in final edited form as: Am J Physiol Lung Cell Mol Physiol. 2007 Jun 8;293(2):L436–L445. doi: 10.1152/ajplung.00097.2007

Fig. 3.

Fig. 3

Pharmacological inhibitors block RSV activation of MAPK pathways. A549 cells were mock treated (vehicle) or treated with p38 inhibitor (SB-203580; A), JNK inhibitor (SP-600125; B), or ERK inhibitor (U-0126; C) before infection with RSV at MOI of 2.5 pfu/cell. Cellular proteins were separated on 10% SDS-PAGE and blotted using antibodies to the phosphorylated (P) form of the MAPKs followed by visualization using the ECL method. As a control, the blots were stripped and reprobed with specific antibodies to the nonphosphorylated MAPKs (n = 2).